ValuEngine upgraded shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) from a sell rating to a hold rating in a research report sent to investors on Tuesday, August 29th.
Several other equities research analysts have also commented on JUNO. Zacks Investment Research lowered Juno Therapeutics from a buy rating to a hold rating in a research note on Tuesday, May 2nd. FBR & Co cut their price target on Juno Therapeutics from $30.00 to $29.00 and set a mkt perform rating for the company in a research note on Friday, May 5th. Wedbush reiterated a neutral rating and issued a $24.00 price target on shares of Juno Therapeutics in a research note on Friday, May 5th. Morgan Stanley cut their price target on Juno Therapeutics from $27.00 to $26.00 and set an equal weight rating for the company in a research note on Monday, May 8th. Finally, Vetr raised shares of Juno Therapeutics to a buy rating in a report on Tuesday, May 23rd. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $34.88.
Juno Therapeutics (NASDAQ JUNO) traded up 7.54% during trading on Tuesday, hitting $45.33. The stock had a trading volume of 4,269,525 shares. The stock has a 50 day moving average of $32.75 and a 200 day moving average of $26.72. The firm’s market capitalization is $4.75 billion. Juno Therapeutics has a one year low of $17.52 and a one year high of $45.75.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.24). The company had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The company’s revenue for the quarter was down 22.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.64) earnings per share. Equities research analysts expect that Juno Therapeutics will post ($3.12) earnings per share for the current fiscal year.
In other Juno Therapeutics news, Director Anthony B. Evnin acquired 9,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The shares were bought at an average cost of $24.40 per share, with a total value of $219,600.00. Following the completion of the acquisition, the director now directly owns 66,301 shares in the company, valued at approximately $1,617,744.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Richard Klausner sold 12,000 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $42.66, for a total transaction of $511,920.00. Following the transaction, the director now directly owns 783,536 shares in the company, valued at $33,425,645.76. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 8,078,369 shares of company stock worth $218,620,477. Corporate insiders own 15.26% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company increased its holdings in Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 228 shares during the period. Pacad Investment Ltd. acquired a new stake in shares of Juno Therapeutics during the second quarter worth $105,000. QS Investors LLC acquired a new stake in shares of Juno Therapeutics during the second quarter worth $135,000. Great West Life Assurance Co. Can lifted its stake in shares of Juno Therapeutics by 80.5% during the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 3,800 shares during the period. Finally, Nisa Investment Advisors LLC acquired a new stake in shares of Juno Therapeutics during the first quarter worth $200,000. 70.76% of the stock is currently owned by institutional investors.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.